KOREA WHO
-
-
-
CEO of Daewoong Pharmaceutical
Park Seong-soo
Daewoong Pharmaceutical's 25-Year 'Nabota Man' Unveils Vision for KRW 1 Trillion in Operating Profit
-
Last Updated on Dec 27, 2024
-
CEO of Daewoong Pharmaceutical
Life Summary
Park Seong-soo is the CEO and President of Daewoong Pharmaceutical.
He shares the co-CEO role with Lee Chang-jae, focusing on overseas business and research and development.
He also serves as CEO of Daewoong Pharmaceutical affiliates, Aficel Therapeutics and Daewoong Investment.
He was born in February 1976.
He graduated from Cheongju Shinhung High School in Chungcheongnam-do and earned a degree in pharmacy from Seoul National University. He also received a master’s degree in medicinal chemistry from Seoul National University Graduate School.
After joining Daewoong Pharmaceutical, he worked as the head of the U.S. branch and as head of the Nabota Business Division.
He was promoted to vice president and then appointed as CEO in 2024.
He has played a leading role in the Nabota business, which has become one of Daewoong Pharmaceutical’s core operations.
He has outlined a vision to achieve KRW 1 trillion (US$ 721.5 million) in revenue from each of Daewoong Pharmaceutical’s three flagship innovative drugs, aiming to usher in an era of KRW 1 trillion (US$ 721.5 million) in operating profit.
#ParkSeongSoo #DaewoongPharmaceutical #Nabota #innovativemedicine #globalbusiness #R&D #pharmaceuticalindustry #CEO #operatingprofit #SeoulNationalUniversity
He shares the co-CEO role with Lee Chang-jae, focusing on overseas business and research and development.
He also serves as CEO of Daewoong Pharmaceutical affiliates, Aficel Therapeutics and Daewoong Investment.
He was born in February 1976.
He graduated from Cheongju Shinhung High School in Chungcheongnam-do and earned a degree in pharmacy from Seoul National University. He also received a master’s degree in medicinal chemistry from Seoul National University Graduate School.
After joining Daewoong Pharmaceutical, he worked as the head of the U.S. branch and as head of the Nabota Business Division.
He was promoted to vice president and then appointed as CEO in 2024.
He has played a leading role in the Nabota business, which has become one of Daewoong Pharmaceutical’s core operations.
He has outlined a vision to achieve KRW 1 trillion (US$ 721.5 million) in revenue from each of Daewoong Pharmaceutical’s three flagship innovative drugs, aiming to usher in an era of KRW 1 trillion (US$ 721.5 million) in operating profit.
#ParkSeongSoo #DaewoongPharmaceutical #Nabota #innovativemedicine #globalbusiness #R&D #pharmaceuticalindustry #CEO #operatingprofit #SeoulNationalUniversity